We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+14.3%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$39.6M
AUM Growth
+$441K
Cap. Flow
-$3.78M
Cap. Flow %
-9.56%
Top 10 Hldgs %
98.69%
Holding
17
New
–
Increased
3
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
ALLK
Allakos
ALLK
+$437K
2
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$3.54K
3
CMPX icon
Compass Therapeutics
CMPX
+$2.28K

Top Sells

Rank Stock Value
1
SCYX icon
SCYNEXIS
SCYX
+$2.69M
2
ACLX
Arcellx
ACLX
+$1.12M
3
CABA icon
Cabaletta Bio
CABA
+$413K

Sector Composition

Rank Sector Weight
1 Healthcare 74.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
1
Savara
SVRA
$1.13B
$13.4M 33.97%
6,896,551
– –
XERS icon
2
Xeris Biopharma Holdings
XERS
$1.52B
$9.84M 24.86%
6,039,028
– –
SPY icon
3
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$6.53M 16.49%
15,947
– –
RZLT icon
4
Rezolute
RZLT
$444M
$2.69M 6.8%
1,403,157
– –
XOP icon
5
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$3.48B
$2.23M 5.64%
17,500
– –
VECT
6
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$1.35M 3.4%
156,651
+429
+0.3% +$3.54K
AMLP icon
7
Alerian MLP ETF
AMLP
$12.7B
$1.14M 2.88%
29,500
– –
MTEM
8
DELISTED
Molecular Templates, Inc.
MTEM
$780K 1.97%
136,866
– –
CMPX icon
9
Compass Therapeutics
CMPX
$369M
$675K 1.71%
211,740
+581
+0.3% +$2.28K
ALLK
10
DELISTED
Allakos
ALLK
$385K 0.97%
86,533
+68,262
+374% +$437K
CABA icon
11
Cabaletta Bio
CABA
$461M
$336K 0.85%
40,581
-44,147
-52% -$413K
ELEV
12
DELISTED
Elevation Oncology
ELEV
$130K 0.33%
68,324
– –
NAMSW icon
13
NewAmsterdam Pharma Warrant
NAMSW
$40.5K 0.1%
21,333
– –
BTWNW
14
DELISTED
Bridgetown Holdings Limited Warrants
BTWNW
$6.97K 0.02%
39,773
– –
LANV.WS
15
DELISTED
Lanvin Group Holdings Warrants
LANV.WS
$4.5K 0.01%
12,000
– –
ACLX
16
DELISTED
Arcellx
ACLX
– –
-36,302
Closed -$1.12M
SCYX icon
17
SCYNEXIS
SCYX
$42.4M
– –
-215,493
Closed -$2.69M

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q1 2023 Portfolio in Review

As of Q1 2023, Caxton Corporation held 17 positions worth $39.6M, up 1.1% from $39.1M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Caxton Corporation withdrew a net $3.78M in Q1 2023, closing 2 positions and reducing 1 holding. Its most notable exit was SCYNEXIS, an estimated $2.69M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 75% a quarter earlier.

Against the trend, Caxton Corporation added an estimated $437K to Allakos.

  • Caxton Corporation added most to Allakos in Q1 2023, an estimated $437K increase.
  • Caxton Corporation's biggest Q1 2023 reduction was Cabaletta Bio, cutting an estimated $413K.
  • Caxton Corporation fully exited SCYNEXIS in Q1 2023, selling an estimated $2.69M.
  • Caxton Corporation's ten largest holdings make up 99% of its $39.6M portfolio in Q1 2023.
  • Caxton Corporation opened 0 new positions and closed 2 in Q1 2023.
  • Caxton Corporation's portfolio value rose 1.1% quarter-over-quarter to $39.6M.

Based on Caxton Corporation's 13F filing for Q1 2023, filed 15 May 2023.